肺癌治療新趨勢：質子治療在精準控癌上的角色

:::

繁簡 EN

News & Message

:::

首頁/

質子治療癌症治療精準醫療肺癌放射線治療

文／放射腫瘤部醫師簡君儒

肺癌放射治療是運用高能量射線照射腫瘤及周邊高風險區域，可單獨使用，或與藥物、手術搭配作為根治性、緩和性或(新)輔助性治療，提高局部控制率或改善症狀。

進行胸腔放射時因鄰近多個重要器官，如肺臟、心臟、食道及骨髓，傳統光子治療（Photon Therapy）在通過腫瘤前後仍會持續釋放能量，導致周邊正常組織接受不必要輻射劑量(圖一)，可能引起肺炎、食道炎、心臟機能受損、免疫功能抑制，或神經功能障礙等情況。

質子治療（Proton Therapy）運用質子束，將能量集中於腫瘤位置，射線通過腫瘤前劑量較光子少，通過後幾乎不再釋放。研究顯示，質子治療可降低約1/3心臟、食道及正常肺臟輻射劑量(圖二)，減少相關副作用，有助於維持治療期間身體狀態與生活品質。此外亦適用於需再度照射的復發患者，可在兼顧治療劑量同時，提供新的治療契機。

近年臨床上發展之立體定位消融放射治療(stereotactic ablative radiotherapy，SABR)通常僅需6次以內照射，結合質子技術運用於適合個案，在維持相同腫瘤控制率時，進一步提升治療便利性與整體生活品質，可與胸腔內、外科或血腫科配合進行。

綜合而言，質子治療在精準控制腫瘤劑量同時，能有效降低輻射劑量於正常器官曝露，減少短期與長期副作用風險，是肺癌患者追求治療效果與生活品質時，值得考慮的放射治療選項。

照射劑量分佈圖

腦部質子治療選項

文獻佐證

Zhang,X.,Li,Y.,Pan,X.,Xiaoqiang,L.,Mohan,R.,Komaki,R.,...& Chang, J. Y. (2010). Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. International Journal of Radiation Oncology* Biology* Physics, 77(2), 357-366.
Liao, Z., Lee, J. J., Komaki, R., Gomez, D. R., O’Reilly, M. S., Fossella, F. V., ... & Mohan, R. (2018). Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non–small-cell lung cancer. Journal of Clinical Oncology, 36(18), 1813-1822.
Nantavithya, C., Gomez, D. R., Wei, X., Komaki, R., Liao, Z., Lin, S. H., ... & Chang, J. Y. (2018). Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non-small cell lung cancer. International Journal of Radiation Oncology* Biology* Physics, 101(3), 558-563.
Giaddui, T., Chen, W., Yu, J., Lin, L., Simone, C. B., Yuan, L., ... & Xiao, Y. (2016). Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. Radiation oncology, 11(1), 66.
ASTRO(American Society for Radiation Oncology)PBT(proton beam therapy)Model Policy [https://www.astro.org/Daily-Practice/Reimbursement/Model-Policies/Model-Policies, accessed 2025/10/23]
Bucknell, N. W., Belderbos, J., Palma, D. A., Iyengar, P., Samson, P., Chua, K., ... & Siva, S. (2022). Avoiding toxicity with lung radiation therapy: an IASLC perspective. Journal of Thoracic Oncology, 17(8), 961-973.
Miften, M., Mihailidis, D., Kry, S. F., Reft, C., Esquivel, C., Farr, J., ... & Wilkinson, J. (2019). Management of radiotherapy patients with implanted cardiac pacemakers and defibrillators: a report of the AAPM TG-203. Medical physics, 46(12), e757-e788.